We deliver high quality, exclusive, tailored solutions from the chemical development to the commercialization of Active Pharmaceutical Ingredients (APIs), cGMP Advanced Intermediates, Highly Potent APIs (HPAPIs) and Anticancer compounds. At HAS Healthcare Advanced Synthesis (HAS), Switzerland, we have been committed to offering the best CDMO standards to our healthcare clients since 1984, with a full range of high-quality, exclusive, personalized solutions. We are passionate about tailoring our services to our clients’ clinical and commercial manufacturing needs and going the extra mile to support them with their analytical and regulatory requirements. We specialize in the delivery of oncology and rare disease compounds and hold a strong track record in reducing time to market for life saving products in these areas. We are extremely proud to have been successfully approved by the Swissmedic, the US FDA, the European EMA and Japanese PMDA, as well as by other national health authorities. Making the difference Sustainability lies at the core of HAS’s values, as we prioritize the accountable use of assets and aim to limit and improve our environmental impact on the local community.